EPS 232 / Epsilogen - LARVOL DELTA

Enhancing affinity of the novel HER2-targeting IgE, EPS 232, elicits superior anti-tumour activity supporting use in cancers with ultra-low HER2 expression (SITC 2025) - "EPS 232 delivered similar TGI in vivo in HER2-low (JIMT-1: 47.41±4.47%; MTLn3: 52.20±13.33%), and ultra-low (MDA-MB-231: 41.28±4.57%) models. The anti-tumour efficacy of EPS 232 in the MTLn3 model was associated with an increase in T cell and macrophage infiltration into the tumour.Conclusions These data demonstrate that the increased HER2 affinity of the IgE therapeutic, EPS 232, improved anti-tumour responses and indicate that EPS 232 could be useful in the clinic for HER2-low and ultra-low indications, including TNBC.Ethics Approval This study was approved by the Axis Bioservices Animal Welfare and Ethical Review Board, and all procedures are carried out under the guidelines of the Animal (Scientific Procedures) Act 1986."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2